Strong Funding Momentum Vizgen has recently secured $48 million in funding from prominent investors such as Merck Ventures, ARCH, and Northpond, indicating robust investor confidence and a solid financial base to expand sales efforts and scale commercialization activities.

Innovative Technology Leadership With the launch of MERFISH 2.0 and its pioneering spatial genomics and proteomics platforms, Vizgen offers cutting-edge solutions that are attractive to research institutions and clinical labs looking to adopt advanced multi-omics tools for high-resolution biological insights.

Strategic Collaborations Partnerships with industry leaders like Hamamatsu and collaborations with Harvard University demonstrate Vizgen's ability to integrate with established players, creating opportunities to offer combined platforms and expand into translational and clinical markets.

Growing Market Presence Recognition as the number one private spatial biology company in 2024 and the launch of the Certified Service Provider Program highlight Vizgen’s increasing market visibility and opportunities to foster strategic partnerships and customer adoption across research and diagnostic sectors.

Expanding Customer Base Recent collaborations, new product launches, and an expanding ecosystem position Vizgen to target academic, biotech, and pharmaceutical organizations actively investing in spatial multi-omics technologies, opening numerous avenues for sales growth and enterprise expansion.